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EFFECT OF INFLIXIMAB THERAPY ON SERUM AND FECAL BIOMARKER 




 Inflammatory Bowel Disease (IBD), divided into Crohn’s disease (CD), 
ulcerative colitis (UC), and indeterminate colitis (IC), is a chronic, crippling autoimmune 
condition characterized by gastrointestinal (GI) inflammation. The methods used to 
diagnose IBD and assess its activity can be invasive and costly and typically include a 
combination of histologic, endoscopic, radiologic, clinical, and biochemical measures. 
Currently, there is an increasing need for the development of noninvasive assessment 
measures to detect an interval response to prescribed therapy. Previous studies have 
found serial and fecal biomarkers to be reliable, but non-specific indicators of GI tract 
inflammation. At present, they cannot be used to distinguish between inflammation 
resulting from infection and that caused by chronic inflammation in patients with IBD.  
 The aim of this study is to measure changes in serum and fecal biomarkers over 
time in individual children and adolescents with CD, UC, and IC initiating infliximab 
therapy while investigating any parallels between fluctuations in biomarker levels and 
endoscopic, clinical, and biochemical outcomes. The inflammatory biomarkers evaluated 
in this study include fecal and serum anti-Saccharomyces-Cerevisiae Antibody (ASCA), 
fecal and serum lactoferrin, fecal hemoglobin, fecal calprotectin, fecal IL1-α, fecal IL1-β, 
C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).   
 
vi 
 The data for this study was collected from a multicenter longitudinal prospective 
cohort study following pediatric patients over the course of six consecutive infliximab 
infusion appointments. Study sites include Boston Children’s Hospital and Riley 
Children’s Hospital in Indianapolis. Participants were recruited from a pool of CD, UC, 
and IC patients who were either new to infliximab, had been receiving infliximab for less 
than six months, or had been receiving infliximab for more than one year. Patients 
brought in stool samples at each of their scheduled infliximab infusions, biochemical labs 
(ESR and CRP) were obtained, and patients completed a health-related quality of life 
survey (IMPACT-III Questionnaire). 
 Forty-three patients (26 with CD, 16 with UC, and one with IC) completed this 
study. There was no significant difference in mean serum or fecal ASCA levels between 
participants with CD and those with UC. However, average serum and fecal ASCA were 
higher in patients with CD than those with UC at almost every infusion. The baseline 
mean CRP level in patients with CD was significantly higher than that observed in 
patients with UC (p<0.05). In patients with CD, the mean IMPACT-III score was 
significantly higher (improved quality of life) at Infusion 5 than at baseline. 
 The data collected in this study suggest serial biomarker measurements may be 
useful in monitoring a patient’s response to infliximab therapy. This study is not yet 
complete and requires further data analysis to more definitively conclude if a single or a 
composite metric including several fecal and/or serum inflammatory biomarkers would 
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Inflammatory Bowel Disease 
 Inflammatory Bowel Disease (IBD), further divided into Crohn’s disease (CD), 
ulcerative colitis (UC), and indeterminate colitis (IC), is a chronic autoimmune condition 
characterized by gastrointestinal (GI) inflammation. While the exact cause of IBD 
remains unknown, the pathogenesis is thought to result from a combination of genetic 
and environmental factors, including alterations in the gut microbiome, defects in the 
innate and adaptive immune systems, and environmental exposures (Shapiro, Subedi, 
LeLeiko, 2016). Inflammatory Bowel Disease is a global disease with a rising burden. 
This increased prevalence in industrialized and developing countries has resulted in a 
parallel growth in the need for research to identify affordable diagnostic measures, 
prevention, and treatment strategies for patients with IBD. (Ng et al., 2017). 
Suspected Pathogenesis 
 The mucosa lining the gut is composed of tightly associated epithelial cells that 
act as a physical defense system, separating the contents of the intestinal lumen from the 
rest of the body. The epithelium is predominantly made up of absorptive enterocytes and 
secretory cells (Allaire, Crowley, Law, Chang, Ko, & Vallance, 2018). These secretory 
cells include goblet cells and small intestine Paneth cells, which regulate mucus 
production and secrete antimicrobial peptides like defensin, respectively (Abraham & 
Cho, 2009). Defects in this barrier are a characteristic feature of IBD, including a 
damaged mucus layer, increased epithelial barrier permeability, and increased microbial 
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contact with the epithelium and triggering of mucosal immune reactions, that when 
excessive, can result in chronic inflammation (Antoni, Nuding, Wehkamp, & Stange, 
2014). 
 
Figure 1: Pathogenesis of Inflammatory Bowel Disease. Genetic and environmental 
factors lead to impaired barrier function, allowing commensal bacteria and microbial 
products from within the gut to gain entrance into the mucosa and submucosa, thereby 
inducing immune cell activation and cytokine production. If left unchecked by adequate 
regulatory anti-inflammatory signaling pathways, the ensuing chronic inflammation 
increases the risk of developing long-term complications, including intestinal stricture 







Genome-wide association studies (GWAS) have discovered over 200 
nonoverlapping genetic risk loci, with approximately 30 identified as being related to CD 
and/or UC (Guan, 2019). Studies of these genes and genetic loci show several pathways 
connected to intestinal homeostasis, resulting from closely regulated interactions between 
epithelial, innate, and adaptive immune cells. A genetic mutation in the nucleotide-
binding oligomerization domain 2 (NOD2) protein is one such genetic factor investigated 
for its role in the pathogenesis of Crohn’s Disease. NOD2 is an intracellular Toll-like 
receptor with a role in sensing bacterial peptidoglycan and activating pro-inflammatory 
pathways to control microbial infections (Al Nabhani, Dietrich, Hugot, & Barreau, 2017). 
A frameshift mutation in the gene encoding NOD2 has been detected in CD patients and 
their family members. This mutation results in increased susceptibility to disease due to 
its loss of function in sensing cytosolic bacteria, leading to a subsequent exaggerated 
adaptive immune response (Ogura et al., 2001). Monozygotic twin studies have shown 
there is a 50-60% concordance of CD in identical twins. However, the near-equal 
percentage of discordance suggests genetic susceptibility is insufficient to explain all IBD 
cases (Halfvarson, Bodin, Tysk, Lindberg, & Jarnerot, 2003). The increase in incidence 
over the last half-century appears to point to environmental challenges as important co-
precipitators in the surge in the incidence and prevalence of IBD in recent years (Danese, 





Role of Environment 
Previously identified non-genetic risk factors associated with IBD development 
include diet, hygiene, cigarette smoking, history of appendectomy, vitamin D 
concentrations, and emotional well-being (stress, depression) (Shapiro, Subedi, & 
Lodhia, 2018). The “hygiene hypothesis” suggests that markers of westernized lifestyles 
including improved sanitation and prevalent antibiotic use, have reduced the presence of 
infectious stressors that would otherwise have favored the development of a more “self-
tolerant” immune system. Thus, children raised in these environments are more 
susceptible to developing atopic and autoimmune disorders (Wills-Karp & Karp, 2001). 
A link between diet and risk of developing IBD has also been established. Studies have 
found that high sucrose intake was associated with a higher risk of IBD, and increased 
saturated animal fat intake and cholesterol were connected with increased UC risk. In 
contrast, increased fructose (fruit sugar) and fluid intake were negatively associated with 
IBD risk (Reif, Klein, Lubin, Farbstein, Hallak, & Gilat, 1997). Interestingly, smoking 
has been found to have disparate effects on the pathogenesis of CD and UC. Smoking 
increases the likelihood of a more severe course of CD (increased disease severity and 
need for surgery), but a protective effect (reduction in disease severity and need for 
surgery) in some UC patients (Rubin & Hanauer, 2000). 
IBD is most prevalent in western populations, and the rising incidence in 
developing countries is thought to be related to the adoption of more western lifestyles 
and dietary preferences (Zhang & Li, 2014). According to a systematic review performed 
in 2018 that examined data from 38 countries, the regions with the highest pediatric IBD 
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burden were Europe and North America, with incidence rates of 23/100,000 and 
15.2/100,000, respectively (Sýkora, Pomahačova, Kreslová, Cvalínová, Štych, & 
Schwarz, 2018). In North America, the incidence of CD was 13.9/100,000, the incidence 
of UC was 10.6/100,000, and the incidence of IC was 2.1/100,000 (Sýkora et al., 2018). 
Globally, there were 67%, 46%, and 11% increases in the prevalence of CD, UC, and IC, 
respectively, over the interval between 1940-2010 in North America and 1951-2017 in 
Europe (Sýkora et al., 2018). Interestingly, one study also suggests the climate may play 
a factor in the incidence of CD and UC. A “North-South gradient” was discovered in the 
United States and France, where CD incidence rates are lower in the southern halves of 
these countries than in the north. A correlation between incidence and distance from the 
equator is supported, as the incidence of CD in New Zealand is also high (Talley et al., 
2011). 
Clinical Presentation of IBD 
 Presenting IBD symptoms vary considerably from patient to patient and can 
include a broad spectrum of intestinal and extraintestinal manifestations. IBD subtypes 
(CD, UC, and IC) share several clinical features, including abdominal pain and diarrhea, 
but are distinguishable using endoscopic and histologic evaluation. The Paris 
Classification is used to classify disease extent, behavior, and location in pediatric 
patients with IBD. Crohn’s disease is the predominant (representing 59-73% of cases) 
IBD subtype in children and adults, followed by UC (24-32% of diagnoses) and IC (3-
13% of IBD cases) (Yu & Rodriguez, 2017).  
 
6 
 Crohn’s disease is distinguishable by its discontinuous pattern, transmural 
inflammation, and potential involvement in any part of the GI tract, mouth to anus. The 
terminal ileum or perianal region is the most frequently affected portion of the GI tract 
(Zhang & Li, 2014). The Paris Classification characterizes CD using the location of 
inflammation, age at diagnosis, the behavior of the observed inflammation (stricturing 
and/or penetrating), and the presence or absence of evidence of growth delay (Assa, 
Rinawi, & Shamir, 2018). Patients typically present with non-stricturing and non-
penetrating disease at diagnosis, with a progression to stricturing or penetrating disease 
for the majority of patients after 25 years (Louis et al., 2003). Studies have shown that the 
age of onset can also affect the severity of disease and clinical presentation. According to 
one study, the younger the patient, the more likely they are to present with isolated 
colonic CD (Levine, 2009). Another study found that childhood-onset CD was more 
likely (43.2%) to be characterized as being “panenteric” or extensive at the time of 
diagnosis, versus 3.2% of adult patients (Limbergen et al., 2008).  
 The mucosal disease noted in patients with ulcerative colitis often begins in the 
rectum, extending, non-continuously, to include a portion of, or all of the colon (Adams 
& Bornemann, 2013). Common clinical features of UC include rectal bleeding, diarrhea, 
urgency, tenesmus (a feeling of incomplete defecation), and abdominal pain. The Paris 
Classification characterizes UC by extent and severity. There are four levels of extent: 
inflammation confined to the rectum is deemed ulcerative proctitis, inflammation 
spanning from the rectum to the splenic flexure is termed left-sided UC, inflammation 
extending to the hepatic flexure is deemed extensive UC, and inflammation extending 
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beyond the hepatic flexure is pancolitis (Ordas, Eckmann, Talamini, Baumgart, & 
Sandborn, 2012).  
 Extraintestinal manifestations of inflammatory bowel disease are common in both 
CD and UC patients and can involve many different organ systems, including rheumatic, 
dermatologic, ophthalmologic, and hematologic (Larsen, Bendtzen, & Nielsen, 2010). A 
study of 1009 pediatric IBD patients found that 28.2% had experienced at least one 
extraintestinal manifestation, with 87% occurring within their first year after diagnosis. 
Additionally, patients classified as having moderate/severe disease were significantly 
more likely to develop extraintestinal manifestations than patients with mild disease or 
more limited disease (Dotson et al., 2010).  
Diagnosis and Classification of IBD 
 It is important to diagnose a patient with IBD only after completing a 
comprehensive clinical, biochemical, endoscopic, histologic, and radiologic evaluation, 
and certainly before starting treatment. Initial steps often include a detailed history and 
physical examination (Flynn & Eisenstein, 2019), and specifically an assessment for risk 
factors like a family history of IBD and other GI diseases and drug history. Physical 
examination should include an assessment for abdominal tenderness, guarding, perianal 
fissures, or fistulas, as well as evidence of any prior or ongoing signs of growth delay 
(Rosen, Dhawan, & Saeed, 2015). Additional parts of a comprehensive diagnostic 
workup include laboratory evaluations, endoscopic studies, histology, and small bowel 
imaging (Levine et al., 2014).  
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 Recommended laboratory studies include blood and stool tests to assess for the 
presence of inflammation, including CRP, ESR, fecal calprotectin, and lactoferrin. Stool 
studies can also assess for specific infectious causes of diarrhea, including C. difficile, 
Salmonella, and parasitic infections (Conrad & Rosh, 2017). ESR is a measure of the rate 
at which erythrocytes settle in plasma. CRP is a molecule formed in the liver and released 
in response to the presence and levels of circulating inflammatory cytokines (Bray et al., 
2016). ESR and CRP are both quite sensitive to assess for inflammation. However, 
neither biochemical marker is specific to gut inflammation. As such, these markers are 
insufficient to diagnose IBD. However, their levels may help assess disease status or 
interval response to therapy (Walsham & Sherwood, 2016).  
Endoscopic and colonoscopic examinations, including subsequent histology, 
allow clinicians to establish an IBD diagnosis and further specify whether the patients 
have CD or UC (Spiceland & Lodhia, 2018). An upper endoscopy is used to observe the 
esophagus, stomach, and the duodenum. Colonoscopy enables a clinician to assess 
directly the mucosa lining the rectum, colon, and end the terminal ileum (or end of the 
small intestine). Although there is no singular classification system for endoscopic 
severity scoring, the Mayo Endoscopic Subscore for UC and the Simple Endoscopic 
Score for CD (SES-CD) are often used in clinical practice (Spiceland & Lodhia, 2018). 
Computed tomography enterography (CTE) can help visualize portions of the GI tract 
typically inaccessible during routine endoscopy, as well as present insight into bowel 
wall thickness and extraintestinal pathology (Park & Lim, 2013). Table 1 below shows 




Table 1: Comparison of diagnosis for UC and CD. (Sairenji, Collins, & Evans, 2017) 
 
Crohn’s Disease 
The Pediatric Crohn’s Disease Activity Index (PCDAI) is used to measure disease 
activity in pediatric patients with Crohn’s Disease. This metric relies on patient-derived 
responses to standardized questions, including the degree of abdominal pain, the number 
of stools per day, general well-being; physical examinations including weight, linear 
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growth, abdominal and perirectal examination, and laboratory studies (ESR, hematocrit, 
and albumin) (Hyams et al., 1991). Scores range from 0-100, with higher scores 
indicating more severe, active disease. A score from 0-10 reflects inactive disease, 
patients with mild disease have PCDAI scores ranging from 10-30, and patients with 
moderate to severe disease have PCDAI scores greater than (Hyams et al., 2005). One 
multi-center study found that average PCDAI scores for patients with inactive, mild, 
moderate, and severe disease were 7, 18.3, 26.2, and 40.5, respectively (Kappelman et al., 
2011). The SES-CD gives scores for ulcers, ulcerated surfaces, affected surfaces, and 
narrowing, with scores ranging from 0-3 for each segment, and a total score range of 0-56 
with higher scores indicating more severe disease (Daperno et al., 2004).  
Ulcerative Colitis 
The Pediatric Ulcerative Colitis Activity Index (PUCAI) is used to measure 
disease activity in pediatric patients with ulcerative colitis. As with the PCDAI, the 
PUCAI relies on a patient’s self-report of abdominal pain and the number of stools per 
day, in addition to the following items: stool consistency, amount of blood in stools, 
nocturnal stooling, and activity level (Turner et al., 2007). Scores range from 0 to 85. 
Scores from 0-9 reflect inactive disease, 10-34 reflect clinically mild disease activity, a 
PUCAI of 35-64 is consistent with moderate disease, and patients with PUCAI scores 
ranging from 65-85 are considered to have severe disease (Turner et al., 2009). 
The Mayo endoscopic score for UC ranges from (Travis, et al., 2013): 
• Normal (0) with no inflammatory signs  
• Mild (1): with moderate erythema  
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• Moderate (2): friability, erosions  
• Severe (3): spontaneous bleeding, ulcerations 
This progression is exemplified in Figure 2.  
 
 
Figure 2: Mayo endoscopic score for ulcerative colitis. A) Score 0=normal; endoscopic 
remission. B) Score 1=mild; erythema, decreased vascular pattern, mild friability. C) 
Score 2=moderate; marked erythema, absent vascular pattern, friability, erosions. D) 




 Biomarkers exist as indicators of normal biological processes, pathogenic 
processes, or responses to an exposure or intervention (Califf, 2018). They may be 
classified as diagnostic, monitoring, prognostic, predictive, and/or 
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pharmacodynamic/response depending on their applications (Califf, 2018). Their utility 
rests in their ability to replace subjective with continuous objective information. 
However, these measurements do not always align with a patient’s experience, well-
being, or clinical state (Strimbu & Tavel, 2010). With respect to IBD, biomarkers may 
help differentiate between UC and CD patients, evaluate disease severity, monitor disease 
activity, and quantify any response to therapy (Rogler & Biedermann, 2015). Currently, 
several biomarkers are used in the diagnosis and interval assessment of IBD patients, 
including Anti-Saccharomyces cerevisiae antibodies (ASCA), fecal lactoferrin and 
calprotectin, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). 
 ASCA are IgG and IgA antibodies directed against mannose sequences of the 
Saccharomyces cerevisiae cell wall (Ben-Ami Shor, Papageorgiou, & Shoenfeld, 2017). 
Several studies indicate that serum ASCA can be useful as an identifier for patients with 
CD, with one study finding ASCA to be highly specific (95%) to CD, with 55% of 
pediatric participants with CD being correctly categorized, compared with only 6% with 
UC, and 5% of participants without IBD (Ruemmele, Targan, Levy, Dubinsky, Braun, & 
Sediman, 1998). Another study found fecal and serum ASCA to be significantly higher in 
patients with CD than those without CD. Similarly, serum ASCA was significantly higher 
in steroid-treated patients with active CD than in those with UC and acute colitis (Tang et 
al., 2017). ASCA was also linked with proximal disease (gastroduodenal and small bowel 




 Lactoferrin is a glycosylated iron-binding glycoprotein expressed in many 
biological fluids, including milk, saliva, and tears. Neutrophils release lactoferrin in the 
blood and tissues in response to inflammation (Siqueiros-Cendon, Arevalo-Gallegos, 
Iglesia-Figueroa, Garcia-Montoya, Salazar-Martinez, & Rascon-Cruz, 2014). Several 
studies have found fecal lactoferrin to be a sensitive and specific marker for measuring 
IBD activity. One such study discovered fecal lactoferrin to be 90% specific for 
identifying inflammation in patients with active IBD, with elevated levels 100% specific 
in pointing away from non-inflammatory conditions, including irritable bowel syndrome 
(IBS) (Kane et al., 2003). Another study found similar results, with fecal lactoferrin 
levels significantly higher in patients with active IBD than those with inactive IBD, IBS, 
and infectious bowel disease (Dai, Liu, Zhao, Hu, & Ge, 2007). Fecal lactoferrin levels 
have been shown to reflect IBD activity. They correlate favorably with other metrics of 
mucosal inflammation, including endoscopic and histological parameters. However, fecal 
lactoferrin levels appear less informative in patients with CD, particularly when 
evaluating patients with primarily ileal disease (Gisbert, McNicholl, & Gomollon, 2009). 
 Calprotectin is also a neutrophilic protein that plays a regulatory role in the innate 
immune response (Abraham, & Kane, 2012). Some of its functions include antifungal 
and antibacterial activity, as well as the induction of apoptosis. Fecal calprotectin is 
significantly elevated in children with active IBD (Joishy et al., 2009). However, like 
lactoferrin, calprotectin is not specific and cannot differentiate patients with CD from 
UC. Similarly, calprotectin levels do not discriminate between inflammation resulting 




 There is no existing cure for IBD. Current treatment goals focus on controlling 
symptoms and achieving and maintaining mucosal (and ultimately histologic) healing. 
Medications used in IBD management include aminosalicylates, steroids, 
immunomodulators, and biologics (Jeong et al., 2019). Therapeutic decisions depend on 
many different factors, including disease activity and extent, location, response to any 
previous treatments, risks associated with medications, disease classification (CD or UC), 
patient preference, and insurance (Carter, Lobo, & Travis, 2004).  
 Aminosalicylates, including sulfasalazine (SASP) and 5-aminosalicylic acid (5-
ASA), have been used to induce and maintain remission in patients with UC. 5-ASA 
works by decreasing interleukin-1(IL-1) and tumor necrosis factor (TNF) activation and 
prostaglandin production, inducing apoptosis, and scavenging reactive oxygen 
metabolites. As such, the therapeutic effect of 5-ASA is local/topical, rather than 
systemic, and it acts to decrease the release of mediators participating in the 
inflammatory process found in the mucosa of IBD patients (Nielson & Munck, 2007). 
Aminosalicylates can be useful as first-line therapy to treat mild to moderate UC and to 
sustain disease remission. While SASP is shown to be moderately effective for the 
treatment of active mild colonic CD, 5-ASA has not been shown to have any clinical 
effect on active CD nor in the maintenance of remission (Nielson & Munck, 2007). 
 Corticosteroid treatment has been heavily used in IBD treatment since the 1950s 
due to its broad-based anti-inflammatory effects. However, long-term use of systemic 
forms is associated with side-effects, including weight gain, hypertension, fluid retention, 
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and diabetes. This led to the development of orally-administered and locally-acting 
steroids with high first-pass metabolism in the liver, like budesonide, that minimizes 
systemic bioavailability while retaining therapeutic effectiveness (Nunes, Barreiro-de 
Acost, Marin-Jimenez, Nos, & Sans, 2013). These non-systemic steroids are most often 
used to achieve, but not maintain, remission in patients with moderate to severe IBD 
disease activity. Studies have demonstrated budesonide is effective for initiation of 
remission in patients experiencing mild to moderate ileal and proximal colonic CD. 
Immunomodulators like 6-mercaptopurine are steroid-sparing and more effective in the 
maintaining disease remission in patients with CD and UC (Kozuch, Rosenfeld, Bressler, 
& Seidman, 2014). Methotrexate is another immunomodulator that is efficacious in 
bringing about and maintaining remission in patients with CD (Feagan et al., 2000).  
 Infliximab is a chimeric monoclonal IgG antibody that binds and neutralizes the 
pro-inflammatory cytokine TNF. It was the first biologic used to treat patients with 
moderate to severe IBD. Infliximab is administered intravenously by weight-based 
dosing (Rutgeerts, Van Assche, & Vermeire, 2004). Infliximab treatment has been found 
to decrease endoscopic and histological disease activity in patients with CD colitis (Nayar 
& Rhodes, 2004). Additionally, a randomized controlled trial of patients with active CD 
demonstrated that patients who initially responded to infliximab were more likely to 
remain in remission after 30 and 54 weeks and more likely to discontinue corticosteroid 
treatment. (Hanauer et al., 2002). Infliximab is also approved to treat patients with UC 
after studies demonstrated that patients with moderate-to-severe active UC on infliximab 
were more likely to enter remission than those treated with placebo (Rutgeerts, et al., 
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2005). Despite these promising results, subsequent studies have found that up to 30% of 
patients experience no clinical benefit from infliximab, and as many as 50% of patients 
lose the clinical response to infliximab, possibly as a result of the development of 
neutralizing antibodies (Papamichael, Lin, Moore, Papaioannou, Sattler, & Cheifetz, 
2019).  
 Several other biologic agents are used to treat patients with IBD, including other 
anti-TNF medications, like adalimumab and certolizumab. However, only infliximab and 
adalimumab are currently FDA-approved for treating IBD in children (Breton, Kastl, 
Conrad, & Baldassano, 2020). Because of the rate of patients (approximately 30%) that 
have no response to anti-TNF agents, or a loss of response due to the development of 
neutralizing antibodies, studies are investigating other biologic agents, namely 
vedolizumab and ustekinumab, for their use in pediatric IBD patients. The biologics 
currently used in the treatment of children and adolescents with IBD are displayed in 
Table 2.  
 Vedolizumab is a monoclonal anti-integrin whose actions inhibit lymphocytes 
from binding to the intestinal endothelium, thus downregulating inflammation specific to 
the GI tract (Conrad et al., 2016). In a study performed on pediatric patients with CD and 
UC, investigators found that after 14 weeks, 76% of patients with UC and 42% of 
patients with CD gained remission. After 22 weeks, patients who had never received anti-
TNFs had 100% remission while remission was seen in 45% of patients that had 
undergone an anti-TNF treatment before the study (Singh et al., 2016). Ustekinumab is a 
monoclonal antibody that binds to cytokines IL-12 and IL-23, blocking the activation of 
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T helper cell-mediated immune response (Pugliese et al., 2019). In a study performed on 
52 pediatric patients with IBD, after one year, 75% were still using ustekinumab, with 
steroid-free remission gained in 50% of the patients who had a previous history of 
biologic treatment, and remission in 90% of biologic-naïve patients (Dayan et al., 2019).  
 
 
Table 2: Biologics Used in Pediatric IBD. (Breton et al., 2020) 
 
Nutrition has been evaluated for its role in the development of IBD but has also 
been studied for its use as a form of treatment. Exclusive enteral nutrition (EEN) has been 
addressed as a path to remission in children and adolescents with Crohn’s disease 
(Penagini et al., 2016). This diet consists of patients fed a liquid formula as their only 
dietary source, orally or by nasogastric tube, with the formula usually being polymeric, 
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elemental, or semielemental (Critch, Day, Otley, King-Moore, Teitelbaum, & Shashidhar, 
2012). This diet is typically maintained for 6-8 weeks, and the choice of the formula is 
made based on various factors, including taste, cost, and availability (Kansal, Wagner, 
Kirkwood, & Catto-Smith, 2013). Studies have shown that EEN induces remission in 
pediatric patients with CD and positively affects mucosal healing. In a study of twenty-
seven children with CD receiving EEN, 80% of those with newly diagnosed CD and 58% 
with “long-standing” disease entered remission (Day et al., 2006). Another study found 
that after ten weeks of EEN therapy or corticosteroid treatment, 74% of children on EEN 
therapy exhibited mucosal healing, compared to 33% of pediatric participants on 
corticosteroids (Critch et al., 2012). 
Health-Related Quality of Life 
 The burden that comes with adapting to a chronic illness, including Crohn’s 
Disease, can significantly impair children’s quality of life. Patients may experience a 
delayed onset of puberty, decreased linear growth, and a need for frequent bathroom 
visits that negatively affect their ability to participate in regular academic and 
extracurricular activities (MacKner, Crandall, & Szigethy, 2006). Health-related quality 
of life (HRQoL) examines how disease burden engages a patient’s overall level of 
functioning and operational psyche. HRQoL can be assessed along multiple dimensions, 
including self-perceived health status and physical and emotional functioning (Yin, Njai, 
Barker, Siegel, & Liao, 2016). These measures can also help assess a patient’s 
psychologic and functional response to a new treatment.  
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 The IMPACT-III questionnaire is a disease-specific HRQoL measure developed 
for assessing children and adolescents with IBD, primarily in research settings (Otley et 
al., 2002). It is a self-report measure with 35 questions covering six realms: Bowel 
Symptoms, Systemic Symptoms, Social Functioning, Body Image, 
Treatment/Interventions, and Emotional Functioning. The responses to each question 
employ a 5-point (1-5) Likert scale, with the total score ranging from 35 to 175. Higher 
scores on this questionnaire suggest a better quality of life. There is an additional final 
open-ended question in which a patient can comment on anything they feel is relevant 






 Prior studies have found that changes in serial inflammatory biomarker 
measurements can be useful indicators in the diagnosis and periodic evaluation of 
patients with known or suspected IBD. The primary goal of this study was to measure the 
serial changes in serum and fecal biomarkers in pediatric patients with CD, UC, and IC 
who initiated therapy with infliximab. The secondary goal was to investigate any link 
between fluctuations in biomarker levels and endoscopic, clinical, and biochemical 
outcomes. The inflammatory biomarkers evaluated in this study included fecal and serum 
ASCA, fecal and serum lactoferrin, fecal calprotectin, fecal hemoglobin, the cytokines 
IL1-α, IL1-β, and ESR and CRP. Additionally, we analyzed the longitudinal impact of 







 This is a prospective open-label, non-randomized and multicenter longitudinal 
cohort study conducted at Boston Children’s Hospital and Riley Children’s Hospital in 
Indianapolis to assess pediatric patients less than 21 years of age receiving 
immunosuppressive therapy with infliximab (Remicade) to treat their IBD. Boston 
Children’s Hospital Institutional Review Board (IRB) approved the study: “Serial Fecal 
Biomarker Measurements Predict Response to Biologic Therapy in Children with IBD” 
(IRB-P00023092).  
 Inclusion criteria included a current diagnosis of Crohn’s Disease, ulcerative 
colitis, or indeterminate colitis and treatment with infliximab infusions at Boston 
Children’s Hospital. Exclusion criteria included an unwillingness to provide serum or 
stool samples at the time of their scheduled infliximab infusions, a patients’ primary GI 
provider’s wish that a patient not be approached for study participation, or if a patient 
refused to provide informed consent or assent.  
 
Study Participants 
 Participants were categorized into three main categories by diagnosis: CD, UC, or 
IC. Three further subcategories were made based on infliximab history. These were 
characterized by a patient’s initial infusion time and how many treatments had been 
received since the initial date. The first of these categories included patients in their 
induction phase, meaning they had received a maximum of three infusions. The second 
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category included patients in the post-induction phase. These patients had obtained more 
than three infusions. However, their participation in the study and first sample collection 
began less than six months after induction. The third and final category included patients 
in a post-induction phase, and most in this group had been treated with infliximab for 
longer than one year. Each study site set out to recruit 50 total patients. 30 patients with 
CD diagnosis (10 induction, 10 <6 months, 10 > 1 year), 15 patients with UC (5 
induction, 5 <6 months, 5 >1 year), and 5 patients with IC from any category. 
 Fifty-nine patients were recruited for the study with a breakdown of 40 CD, 18 
UC, and 1 IC. Forty-three participants have completed the study or are close to 
completion with a distribution of 26 CD, 16 UC, and 1 IC. Of the CD patients, nine are in 
the induction phase, seven are in the post-induction phase less than six months, and ten 
are in the post-induction phase for over one year. Of the UC patients, six are in the 
induction phase, five are in the post-induction phase for less than six months, and ten are 
in the post-induction phase for over one year. The IC patient is in the post-induction 
phase for over one year. 
 
Patient Selection and Recruitment 
 Eligible patients were identified using PowerChart, an electronic medical record 
database at Boston Children’s Hospital. Additional data abstract from consented/enrolled 
patients included IBD history, patient demographics, and infliximab dose/dosing interval. 
With permission from primary GI providers, patients were approached in the ambulatory 
clinics at either the Waltham or Longwood campuses of Boston Children’s Hospital.  
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 Patients were told that they would be followed post-consent and enrollment for 
their next six infliximab infusions if they agreed to participate. At each appointment, a 
5mL blood sample was drawn coincident with the placement of their IV for infliximab 
infusion, a stool sample was provided by the patient (minimum one tablespoon in volume 
obtained within 72 hours of the appointment), and the patient completed an IMPACT-III 
form. Participants would be provided with six individual stool kits that included a plastic 
stool hat, wooden tongue depressor for stool transfer, disposable gloves, a protective 
mask, specimen cup, and a biohazard bag. Participants received $35 in compensation for 
each stool study sample they provided. Patients were given unrestricted time to read and 
review the consent form and sign if over 18 years of age. For patients under 18 years, 
Research Coordinators attained parental consent and child assent. Each enrolled patient 
received a unique study ID number to ensure confidentiality.  
 
Sample Processing and Shipment 
 Research Study Coordinators processed each patient’s blood and fecal samples. 
Fecal samples were separated into three aliquots under a fume hood, labeled with the 
patient’s ID number, and kept in a -80°C freezer. Whole blood samples were separated 
into their respective components by centrifuging for 10 minutes at 25°C and 3000rpm. 
With a pipette, the layer of serum was removed from the centrifuged blood samples and 
separated into three 1mL aliquots labeled with the patient’s unique ID number and kept in 
a -80°C freezer.  
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 Serum and fecal samples were collected and batch shipped to TECHLAB®Inc. in 
Blacksburg, Virginia, for analysis approximately every two to three months. Samples 
were placed in a Styrofoam shipping box on dry ice. A printed list of all included samples 
was also included in the shipment to aid in organization.  
 
Data Collection 
 All the study data was recorded on the Research Electronic Data Capture 
(REDCap) website. This website was utilized by both the Boston Children’s Hospital and 
Riley Children’s Hospital research teams to collect and record data. Due to data sharing 
between these two teams, protected health information (PHI) was omitted. REDCap 
reports (Figures 3-16) included: patient demographics, medication list, disease location, 
Paris classification, infusion data, IMPACT-III questionnaire answers, enrollment and 























Figure 4. Paris classification 
 
 
























































































 Eight hundred thirty-six patients were evaluated for eligibility status, 291 of 
which were found through PowerChart, 507 from a Remicade Visit list, and 38 from 
Pathology cases. Fifty-nine patients were consented and enrolled. Table 3 shows the 
demographic data of the enrolled patient population. Table 4 displays the categorization 
of recruitment results. 
 
 








Table 4. Patient Population: Table of the enrolled patient population by diagnosis and 
Remicade phase (n=59). 
 
Of the 59 total patients that enrolled in the study, 16 dropped out. Six patients 
withdrew for personal reasons, five patients were withdrawn because they were no longer 
having Remicade infusions, four patients were withdrawn from the study for lack of stool 
samples, and one patient was withdrawn because they were no longer a patient of Boston 
Children’s Hospital. At present, 43 patients have completed the study (26 CD, 16 UC, 
and 1 IC). A flowchart of all enrolled patients and their distribution based on diagnosis 










Figure 17. Enrolled Patient Population: Flowchart of enrolled patients organized by 




Baseline Infusion Biomarker Levels 
 Samples were obtained and analyzed from 57 patients at their baseline 
appointments. These 57 patients were further broken down by diagnosis: 38 CD, 18 UC, 
and 1 IC. A total of 51 serum samples were analyzed from 33 participants with CD, 17 
participants with UC, and one participant with IC. Thirty-seven fecal samples were 
analyzed from 25 participants with CD, 11 participants with UC, and one participant with 
IC. Not all patients provided serum and stool samples at each visit, which explains the 
disparate number of patient samples reported and analyzed in this study.  
Serum samples were assessed for ASCA and lactoferrin levels, while fecal 
samples were assessed for ASCA, lactoferrin, hemoglobin, calprotectin, IL1- α, and IL1- 
β levels. ESR and CRP levels were measured using whole blood samples taken from 
patients at their infusion appointments by nursing staff and were processed at the in-
hospital labs. 
 The biomarker levels at the baseline infusion for CD, UC, and IC patients are 
displayed in Table 5. The same statistical analysis performed for CD and UC patients 




Table 5. Baseline Biomarker Data. This table displays measurements from patients at 
their baseline infusion. Biomarker levels were obtained from serum, fecal, and whole 
blood lab samples. A) CD Baseline Data. This table displays data for patients with CD at 
their baseline infusion. B) UC Baseline Data. This table displays data for patients with 
UC at their baseline infusion. C) IC Baseline Data. This table displays data for the single 




Fecal and Serum ASCA by Infusion 
 The data shown in Figure 18 displays the mean fecal ASCA levels for 
participants with CD, UC, and IC from the baseline appointment through Infusion 5. 
Mean fecal ASCA levels for CD patients were highest at Baseline, with an average 
decrease through Infusion 4 and an increase at Infusion 5. Mean fecal ASCA levels for 
UC patients were lowest at Infusion 2 and highest at Infusion 4. There was no significant 
difference in mean fecal ASCA levels between participants with CD and those with UC 
at any infusion. The largest disparity in mean fecal ASCA levels between patients with 
CD and those with UC was recorded at the baseline appointment (p=0.11). The 
differences in mean fecal ASCA levels for CD patients and UC patients, respectively, 
between each infusion (i.e., Baseline to Infusion 1, Infusion 1 to Infusion 2, etc.) were not 
significant. Fecal ASCA levels are considered elevated when an optical density over 
0.110 is recorded. Throughout the study, seven fecal ASCA recordings were “high” for 
CD patients. One patient had high levels at Baseline (0.597) and Infusion 4 (0.176), 
another patient had high levels at Infusion 3 (0.169) and Infusion 5 (0.237), and three 
other patients with CD had high levels at Baseline (0.193), Infusion 1 (0.181), and 
Infusion 2 (0.2). Only one UC patient had a high fecal ASCA level, 0.114, recorded at 
Infusion 4. 
 Data shown in Figure 19 displays the mean serum ASCA levels for participants 
with CD, UC, and IC from the baseline appointment through Infusion 5. Mean serum 
ASCA levels for CD participants were highest at Infusion 2 and lowest at Infusion 5. UC 
participants had mean serum ASCA levels that increased from Baseline to Infusion 4, 
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then decreased at Infusion 5. No significant difference in mean serum ASCA level 
between CD and UC participants was found at any infusion. The largest difference in 
mean serum ASCA level between participants with CD and those with UC, trending 
towards significance, was at Infusion 2 (p=0.06). There was no significant difference in 
mean serum ASCA levels between infusions for CD or UC patients, respectively. A high 
serum ASCA level is any value over 0.08 optical density. Throughout the study, only one 
UC patient had a high serum ASCA level, recorded at three of their infusions: Infusion 2 
(0.096), Infusion 3 (0.094), and Infusion 4 (0.108). For CD patients, there were four 
recorded high serum ASCA levels at Baseline, two at Infusion 1, five at Infusion 2, and 
one at Infusion 3, 4 and 5. One CD patient had high serum ASCA levels at all four of the 
infusions they were able to provide serum samples for (0.125 at Infusion 1, 0.126 at 
Infusion 2, 0.232 at Infusion 4, and 0.194 at Infusion 5). At each infusion the IC patient 
presented samples for, they had the lowest fecal and serum ASCA levels out of all three 
groups. Though not to a significant degree, this data is consistent with findings in other 
studies that reported serum ASCA to be higher in patients with CD than those observed 





Figure 18. Average Fecal ASCA Levels by Infusion. This figure compares mean fecal 




Figure 19. Average Serum ASCA Levels by Infusion. This figure compares mean 









































































Fecal and Serum Lactoferrin by Infusion 
The data shown in Figure 20 displays mean fecal lactoferrin levels for 
participants with CD, UC, and IC from the baseline appointment through Infusion 5. For 
patients with CD, mean fecal lactoferrin levels were highest at Infusion 1 and lowest at 
Infusion 2. For patients with UC, mean fecal lactoferrin levels were highest at Infusion 5 
and, similar to patients with CD, lowest at Infusion 2. No significant difference was 
found between mean fecal lactoferrin levels for participants with CD and UC for any of 
the infusions. Likewise, no significant difference in mean fecal lactoferrin level was 
found for CD or UC patients, respectively, between infusions. A fecal lactoferrin value 
above 7.25 µg/g is considered high. A total of 13 out of 25 CD patients had elevated 
levels of fecal lactoferrin at the baseline appointment (highest recorded: 97, 98, and 288 
µg/g), 11 out of 23 at Infusion 1 (highest recorded: 366 and 882 µg/g), 7 out of 19 at 
Infusion 2 (highest recorded: 87 µg/g), 6 out of 14 at Infusion 3 (highest recorded: 118 
and 193 µg/g), 5 out of 12 at Infusion 4 (highest recorded: 65 µg/g), and 3 out of 7 at 
Infusion 5 (highest recorded: 203 µg/g). At Baseline, three UC patients had high values 
(89, 121, and 351 µg/g), at Infusion 1, four patients had high values (8, 12, 710, and 834 
µg/g), at Infusion 2, 3 out of 9 patients had high values (34, 38, and 206 µg/g), at 
Infusion 3, 2 out of 6 patients had high values (9 and 289 µg/g), at Infusion 4, 2 out of 7 
patients had high values (208 and 304 µg/g), and at Infusion 5, one out of 6 patients had a 
high value (2380 µg/g). 
The data presented in Figure 21 displays the mean serum lactoferrin levels for 
participants with CD, UC, and IC from the baseline appointment through Infusion 5. For 
 
47 
participants with CD, mean serum lactoferrin levels steadily increased from Baseline to 
Infusion 3, then decreased through Infusion 5. For participants with UC, mean serum 
lactoferrin levels increased from Baseline through Infusion 4, then slightly decreased at 
Infusion 5. There was no significant difference between mean serum lactoferrin levels for 
CD and UC participants at any infusion. Likewise, there was no significant difference in 
mean serum lactoferrin level for CD or UC patients, respectively, between infusions. 
There is no standard level of serum lactoferrin considered to be a high value. 
 
 
Figure 20. Average Fecal Lactoferrin Levels by Infusion. This figure compares the 









































Figure 21. Average Serum Lactoferrin Levels by Infusion. This figure compares mean 
serum lactoferrin levels measured from CD, UC, and IC patients from Baseline to 
Infusion 5. 
 
Fecal Calprotectin by Infusion 
The data shown in Figure 22 displays the mean fecal calprotectin levels for 
participants with CD, UC, and IC from the baseline appointment through Infusion 5. For 
patients with CD and the single IC patient, mean levels of fecal calprotectin were highest 
at Infusion 3 and lowest at Infusion 2. For patients with UC, mean levels of fecal 
calprotectin were highest at Infusion 1 and lowest at Infusion 2. There was no significant 
difference in average levels of fecal calprotectin between patients with CD and UC at any 
infusion. Additionally, no significant difference for participants with CD or UC was 
found between the different infusions. 
Fecal calprotectin levels above 50-120 µg/g are considered high, while levels 









































levels, while 12 had abnormally high levels, 800 µg/g being the highest. At Infusion 1, 
five patients with CD had high fecal calprotectin levels and seven had abnormally high 
levels, with 1142 µg/g the highest recorded value. At Infusion 2, five patients with CD 
had high levels and three had abnormally high levels, with 603 µg/g, the highest 
recorded. At Infusion 3, one patient with CD had a high fecal calprotectin level, while 
five had abnormally high levels reaching 1309 µg/g. At Infusion 4, three participants with 
CD had high fecal calprotectin and four had abnormally high levels, with a max of 857 
µg/g. Finally, at Infusion 5, five patients with CD had abnormally high fecal calprotectin, 
with 616 µg/g, the highest recorded value.  
Three patients with UC had high baseline fecal calprotectin levels, and two had 
levels reaching 400 µg/g. At Baseline, one UC patient’s calprotectin level was 
determined QNS. At Infusion 1, two UC patients had abnormally high calprotectin 
reaching 1088 and 1285 µg/g. At Infusion 2, two UC patients had high calprotectin and 
one had an abnormally high value of 455 µg/g. At Infusion 3, one participant had an 
abnormally high value of 1286 µg/g. At Infusion 4, two patients had high values and two 
had abnormally high calprotectin (700 and 823 µg/g). At Infusion 5, one UC patient had 
high calprotectin, while one other had an abnormally high value (1429 µg/g). The same 
patient consistently had the highest calprotectin levels of the UC group for all infusions 





Figure 22. Average Fecal Calprotectin Levels by Infusion. This figure compares the 
mean fecal calprotectin levels measured from CD, UC, and IC patients from Baseline to 
Infusion 5. 
 
Fecal Hemoglobin by Infusion 
The data shown in Figure 23 displays the mean fecal hemoglobin levels for 
participants with CD, UC, and IC from the baseline appointment through Infusion 5. 
Average fecal hemoglobin levels for CD participants were lowest at Infusion 4 and 
highest at Infusion 5. UC patients had the highest mean fecal hemoglobin level at 
Infusion 1, and lowest at Infusion 2. The IC patient had zero detected fecal hemoglobin 
from the baseline appointment through Infusion 4, and no sample was provided 
coincident with Infusion 5. No significant difference in mean fecal hemoglobin levels 
was found between patients with CD and those with UC at any infusion. There was 
additionally no significant difference in mean fecal hemoglobin level between infusions 
































Fecal Calprotectin by Infusion CD UC IC
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A fecal hemoglobin level higher than 15 µg/g is considered high. For participants 
with CD, two had high fecal hemoglobin at Baseline (18 and 39 µg/g), three at Infusion 1 
(22, 30, and 77 µg/g), one at Infusion 2 (34 µg/g), one at Infusion 3 (36 µg/g), none at 
Infusion 4, and one at Infusion 5 (31 µg/g). For UC patients, three had high fecal 
hemoglobin at Baseline (59, 405, and 543 µg/g), two at Infusion 1 (3410 and 4874 µg/g), 
none at Infusion 2, one at Infusion 3 (283 µg/g), two at Infusion 4 (34 and 77 µg/g), and 
one at Infusion 5 (59 µg/g). For the two UC participants with the high fecal hemoglobin 




Figure 23. Average Fecal Hemoglobin Levels by Infusion. This figure compares the 








































Fecal IL1-α by Infusion 
The data shown in Figure 24 displays the mean fecal IL1-α levels for participants 
with CD, UC, and IC from the baseline appointment through Infusion 5. For CD patients, 
the mean fecal IL1-α level increased from Baseline to Infusion 1, then steadily decreased 
through Infusion 5. For UC participants, mean fecal IL1-α was highest at Infusion 2 and 
lowest at Infusion 5. The IC participant had a high IL1-α level of 3834 pg/g at Baseline, 
with a low IL1-α of 26 at Infusion 2. 
There was no significant difference in mean fecal IL1-α level between 
participants with CD and UC at any infusion. There was also no significant difference in 
mean IL1-α level between infusions for CD or UC patients, respectively. Fecal IL1-α 
levels above 2051 pg/g are considered high. For CD patients, three had high fecal IL1-α 
at Baseline (2486, 3324, and 25531 pg/g), five at Infusion 1 (4568, 5243, 6656, 11012, 
and 13192 pg/g), three at Infusion 2 (4104, 4282, 4541 pg/g), and two at Infusion 3 (2068 
and 2691 pg/g). For UC patients, one had high fecal IL1-α at Infusion 1 (5926 pg/g), two 




Figure 24. Average Fecal IL1-α Levels by Infusion. This figure compares the mean 
fecal IL1-α levels measured from CD, UC, and IC patients from Baseline to Infusion 5. 
 
 
Fecal IL1-β by Infusion 
The data shown in Figure 25 displays the mean fecal IL1-β levels for participants 
with CD, UC, and IC from the baseline appointment through Infusion 5. There was no 
significant difference found in mean fecal IL1-β levels CD and UC participants at any 
infusion. Additionally, there was no significant difference in mean fecal IL1-β level 
between any infusions for CD or UC participants, respectively. A fecal IL1-β level above 
101 pg/g is deemed high. For CD patients, high IL1-β levels were seen by three at 
Baseline (714, 1780, and 28300 pg/g), three at Infusion 1 (163, 530, and 13500 pg/g), 
two at Infusion 2 (638 and 2030 pg/g), four at Infusion 3 (317, 367, 27300, and 37757 
pg/g), one at Infusion 4 (238), and two at Infusion 5 (244 and 4163 pg/g). For UC 
patients, high IL1-β levels were seen by two at Baseline (5937 and 18304 pg/g), three at 


































3 (483, 1009, 24810 pg/g), two at Infusion 4 (8206 and 91541 pg/g), and one at Infusion 
5 (97618 pg/g). One UC participant had a 1,190% increase in fecal IL1-β level from 
Infusion 4 to Infusion 5. 
 
Figure 25. Average Fecal IL1-β Levels by Infusion. This figure compares the mean 
fecal IL1-β levels measured from CD, UC, and IC patients from Baseline to Infusion 5. 
 
 
ESR by Infusion 
The data shown in Figure 26 displays the mean levels of ESR for participants 
with CD, UC, and IC from the baseline appointment through Infusion 5. No significant 
difference in mean ESR level was discovered between participants with CD and UC at 
any infusion. There was no significant difference in mean ESR level between infusions 
for CD or UC patients, respectively. The difference in mean ESR level between 
participants with CD and those with UC at Infusion 2 was trending towards significant 
(p=0.07). A high ESR level was noted above 35 mm/hr. For patients with CD, elevated 

































and 52 mm/hr), one at Infusion 2 (52 mm/hr), and one at Infusion 4 (54 mm/hr). UC 
patients did not have a high ESR level at any infusion. 
 
Figure 26. Average ESR Levels by Infusion. This figure compares the mean ESR levels 
measured from CD, UC, and IC patients from Baseline to Infusion 5. 
 
CRP by Infusion 
The data shown in Figure 27 displays the mean CRP levels for participants with 
CD, UC, and IC from the baseline appointment through Infusion 5. CRP levels were 
significantly higher for participants with CD than participants with UC both at Baseline 
(p=0.005) and at Infusion 1 (p=0.015). Mean CRP levels for CD participants steadily 
increased until Infusion 3, after which they decreased through Infusion 5. For UC 
participants, the mean CRP level steadily increased until Infusion 2, decreased at Infusion 
3, and peaked at Infusion 4, with a subsequent decrease at Infusion 5. A high CRP level is 
considered to be any value above 0.5 mg/dL. For CD participants, high CRP level was 































Infusion 1 (0.74, 0.92, 0.99, and 1.34 mg/dL), three patients at Infusion 2 (0.61, 1.42, and 
3.5 mg/dL), two patients at Infusion 3 (1.31 and 5.62 mg/dL), one patient at Infusion 4 
(1.66 mg/dL), and one patient at Infusion 5 (0.7 mg/dL). For UC participants, high CRP 
level was seen in two patients at Infusion 2 (0.53 and 1.16 mg/dL) and two patients at 
Infusion 4 (0.73 and 4.93 mg/dL). One CD participant saw an increase in CRP levels 
between Infusion 2 and 3 of 18,633%. 
 
Figure 27. Average CRP Levels by Infusion. This figure compares the mean CRP 
levels measured from CD, UC, and IC patients from Baseline to Infusion 5. CRP levels 
between the CD and UC groups are significantly different at Baseline (p<0.05) and 




 Participants at each infusion appointment completed an IMPACT-III 
questionnaire. Higher scores suggest a better quality of life. The data presented in Table 
6 shows the mean IMPACT-III scores for CD, UC, and IC patients for each subcategory 
































participant group at each infusion is displayed in Figure 28. There is a significant 
difference in the average total IMPACT-III score for CD patients between the baseline 
appointment and Infusion 5 (p=0.006). Although there was an increase in the mean total 
IMPACT-III score for UC patients between Baseline and Infusion 5, the difference is not 
significant (p=0.16). 
 
Figure 28. Average Total IMPACT-III Scores by Infusion. This figure shows the 
mean total IMPACT-III scores for CD, UC, and IC patients from Baseline to Infusion 5. 
There is a significant difference between the mean total scores of the CD group at 











































Table 6. IMPACT-III Scores: This table displays the scores from the IMPACT-III 
Questionnaire. A) CD IMPACT-III Scores. Table displays mean ± SD scores for CD 
patients from Baseline to Infusion 5. B) UC IMPACT-III Scores. Table displays mean ± 
SD scores for UC patients from Baseline to Infusion 5. C) IC IMPACT-III Scores. 











 Prior studies have found serial and fecal biomarkers to be reliable, but non-
specific indicators of GI inflammation, and useful in the diagnosis and periodic 
assessment of disease activity in patients with IBD. This study aimed to extend our 
understanding of serial and fecal biomarker measurements through a longitudinal 
evaluation in children and adolescents with IBD. This study’s primary goal was to assess 
serum and fecal biomarkers (ASCA, lactoferrin, calprotectin, ESR, CRP) and cytokines 
over time in children and adolescents with Crohn’s Disease, ulcerative colitis, or 
indeterminate colitis that were initiating infliximab therapy. The secondary goal was to 
investigate any connections in the fluctuations of levels of inflammatory biomarkers and 
endoscopic, clinical, and biochemical outcomes. We additionally used an IMPACT-III 
questionnaire to assess patient HRQoL. 
 Recruitment for this longitudinal cohort study is complete. However, further 
sample processing is needed before the final analysis of the data can occur. This analysis 
will enable us to understand better how clinicians can employ biochemical and fecal 
biomarker measurements into clinical diagnostic and management algorithms. 
Additionally, no statistical analysis was possible in the IC group, as we could only recruit 
one patient to this cohort. 
This study’s data are consistent with previous findings that reported elevated 
serum ASCA to be higher in patients with Crohn’s than patients with ulcerative colitis. 
Our results also further demonstrated the previous finding that serum ASCA is increased 
in patients with CD and active disease. The data from fecal ASCA measurements in this 
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study are also promising. Excluding outliers, fecal ASCA was generally higher in 
participants with CD than those measured in participants with UC. However, there were 
no significant changes in levels of serum and fecal ASCA observed in the interval 
between baseline and infusion 5 for participants with CD or UC.  
 Baseline mean levels of serum and fecal ASCA trended higher in participants 
with CD than those measured in participants with UC (p=0.10). Average levels of serum 
and fecal ASCA were generally higher for participants with CD than UC participants. 
The exception to this occurred with measurements made coincident with the fourth 
infliximab infusion. Average fecal ASCA levels for participants with CD were highest at 
baseline. These levels fell briefly at infusion four and rebounded at infusion 5. The 
increased average fecal ASCA levels observed in UC patients at infusion 4 were likely 
due to outliers collected from a single patient. This patient was completing a course of 
antibiotics for streptococcal pharyngitis and otitis media at the time of this infusion. The 
antibiotics had precipitated worsening GI symptoms, including abdominal pain and more 
frequent bowel movements. Interestingly, although this patient had an increased fecal 
ASCA level, as well as elevated fecal biomarker levels (lactoferrin, calprotectin, and 
hemoglobin), IL1-α and IL1-β, and CRP levels, his serum ASCA level was not elevated. 
This speaks to the lack of specificity to these inflammatory biomarkers.  
 One participant with CD who had elevated serum ASCA, fecal calprotectin, and 
fecal lactoferrin at the baseline appointment and infusion 1 withdrew shortly after that 
due to a lack of response to infliximab and per medical records was in the midst of a CD 
flare. Another patient with CD had high serum ASCA levels at infusions 1, 2, 4, and 5. 
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This patient did not provide a serum sample either at baseline or at infusion 3. This 
patient’s fecal ASCA levels were normal/low at baseline and infusions 1 and 2. However, 
the fecal ASCA measurements rose at infusions 3 and 5 (no fecal sample was available at 
infusion 4). This patient also had a high fecal calprotectin level at infusion 1 and an 
elevated IL1-β level recorded at infusion 5. However, there was no documentation 
indicating that these elevations may have been related to a flare in underlying IBD 
disease activity.  
Another patient with CD and a high serum ASCA level at infusion two was 
reported to experience a flare. This patient subsequently developed neutralizing 
antibodies to infliximab by infusion 3. The patient’s follow-up serum and stool samples 
have not yet been processed. Nonetheless, the patient withdrew from the study shortly 
after infusion five due to a change in biologic medication.  
The average serum lactoferrin levels trended higher for participants with CD than 
participants with UC from baseline through infusion 3, though these changes did not 
reach statistical differences. Mean serum lactoferrin levels were highest for participants 
with CD at infusion three and highest for participants with UC at infusion 4. Although 
average serum lactoferrin was higher for UC patients at infusion 4, the median serum 
lactoferrin was higher for CD patients. This finding suggests that outliers may have 
driven the higher average serum lactoferrin level within the UC group.  
Average fecal lactoferrin levels at each infusion were higher for participants with 
UC than participants with CD, though these differences did not reach statistical 
significance. The highest recorded mean fecal lactoferrin levels for UC patients was at 
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infusion 5. However, the median UC fecal lactoferrin value measured at this infusion was 
lower for UC than CD patients. The increased mean value was likely due to the 
disproportionate impact of one outlier within the UC group, who had a fecal lactoferrin 
value of 2390 µg/g and an elevated fecal IL1- β (97618 pg/g). This same patient recorded 
elevated levels of fecal lactoferrin at each infusion and had been admitted to Boston 
Children’s Hospital before his baseline appointment to manage a flare of IBD. Although 
this patient also had elevated fecal IL1- β, fecal hemoglobin, and fecal calprotectin at 
every infusion (except for infusion 3), they had low serum and fecal ASCA levels at each 
infusion. Several months after completing this study, this patient was taken off infliximab 
and switched to another medication due to an inadequate clinical response. Taken 
together, these findings support those reported in other studies that found fecal lactoferrin 
to be a sensitive marker of inflammation in patients with active IBD, as well as that 
ASCA is more specific for CD. 
No significant difference was found in the average level of fecal calprotectin from 
the baseline appointment to infusion 5 for either the CD or UC groups. Additionally, no 
significant difference in average fecal calprotectin level was found between CD and UC 
participants at any infusion. Mean fecal calprotectin level was highest for CD patients at 
infusion 3 and highest for UC patients at infusion 1. Overall, more CD patients had 
abnormally high fecal calprotectin levels (36) compared to UC patients (9). We also 
observed that patients (both CD and UC) who had high fecal calprotectin levels were also 
likely to have high fecal lactoferrin levels.  
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Average fecal hemoglobin levels were higher for patients with UC than those with 
CD at each infusion except infusion 2. Mean fecal hemoglobin levels for UC participants 
increased between baseline and infusion 1, then decreased at infusion 2, increased at 
infusion 3, and decreased during infusions 4 and 5. For the UC group at infusion 1, of the 
ten samples analyzed, eight had fecal hemoglobin levels of 0 µg/g, while two outlier 
samples had recordings of 3410 and 4874 µg/g. Both these participants saw increases in 
their fecal hemoglobin levels of 841% and 898% between baseline and infusion 1. These 
patients also saw increases in fecal lactoferrin between infusions, suggesting that several 
of the biomarkers included in this study may be used individually or in combination to 
more reliably predict mucosal inflammation. The median fecal hemoglobin level for 
participants with CD and those with UC at all infusions was 0 µg/g. There was no 
significant difference in mean fecal hemoglobin level between the CD and UC groups at 
any infusion, nor was there a significant difference in average fecal hemoglobin level 
between infusions for those with CD or UC. Additionally, there was no significant 
difference in fecal hemoglobin levels measured between baseline and infusion 5 for the 
CD or UC group. 
Patients with CD experienced an increase in mean fecal IL1-α levels between 
baseline and infusion 1, then a subsequent decrease through infusion 5. Patients with UC 
saw an increase in fecal IL1-α level from baseline to infusion 2, then a subsequent 
decrease to infusion 5. There were no overall trends in mean fecal IL1- β levels for CD 
and UC participants. Interestingly, of the two patients with UC that had elevated fecal 
IL1- β levels at infusion 4, only one also had an elevated fecal IL1-α level, while the 
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other had an IL1-α of 0 pg/g. At infusion 5, only one patient with UC had a fecal IL1- β 
value that was not 0, and they additionally had an elevated fecal IL1-α level. There was a 
spike in mean fecal IL1- β level at infusion 1, 4, and 5 in patients with UC. These spikes 
paralleled increases observed for other biomarkers like fecal calprotectin and fecal 
lactoferrin for the UC group, suggesting IL1- β may be helpful in the periodic assessment 
of inflammation in patients with UC. 
Average ESR levels were highest for patients with UC at infusion one, and 
highest for the UC group at infusion 4. An elevated ESR level at each infusion was only 
seen in participants with CD. No significant difference in mean ESR levels was found 
between the CD group and UC group at any infusion, though the difference was trending 
towards significance at infusion 2 (p=0.07). Mean CRP level in patients with CD was 
significantly higher than patients with UC at baseline and infusion 1. The average CRP 
level was higher in patients with CD than those with UC at each infusion except infusion 
4. This elevated mean CRP level at infusion 4 was attributed to one patient with UC, who 
was experiencing increased GI symptoms at the time of his infusion, potentially 
attributed to infections and antibiotic treatment. The highest mean CRP level for patients 
with CD parallels the infusion at which the CD group saw the highest mean serum 
lactoferrin and fecal IL1- β levels. One CD patient had an 18,633% increase in their CRP 
level between infusion 2 and 3. According to clinical notes, around this time, the patient 
stopped taking mesalamine in conjunction with infliximab. At infusion 4, this patient’s 
CRP levels were within normal ranges. Though ESR and CRP are non-specific to IBD, 
 
65 
the increase in the levels of these biomarkers did coincide with the increase in other 
studied biomarkers.  
Mean total IMPACT-III scores increased between the baseline infusion and 
infusion 5 in patients with CD and UC. The increase reached significance for patients 
with CD, who saw an average increase of 10.7 points. The increase for patients with UC 
was 8.1 points. The increases in mean total IMPACT-III scores for participants with 
Crohn’s or ulcerative colitis suggest that a positive clinical response to infliximab therapy 
can result in positive clinical and functional treatment outcomes for IBD patients. 
The execution of this longitudinal ambulatory study presented several logistical 
challenges and limitations. This model required patients and their families to remember 
to bring in stool samples to each scheduled infliximab infusion. Even with phone and 
email reminders from Research Study Coordinators, samples were not always provided 
on-schedule. Additionally, several unforeseen scheduling changes led to an inability to 
collect samples or IMPACT-III questionnaires from patients. Ultimately, this resulted in 
disparate numbers of samples and clinical data points recorded for different patients. 
Thus far, this study has had several statistically significant findings and several 
results trending towards significance. However, the current sample size and disparate 
numbers of samples at each infusion limit the applicability of results to the general 
patient population. Future studies should aim to increase patient recruitment efforts and 
establish larger patient cohorts. This may lead to increased statistical power, and 
confidence in results of data analysis.  
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At present, there are no active patients in this study. All 59 patients that were 
initially enrolled have either completed the study or withdrawn. However, there remain 
40 serum and 23 stool samples that have been shipped to TECHLAB® in Virginia and 
are in the process of being evaluated for biomarker levels. Once data analysis has been 
performed on these samples and compiled with data from Riley Children’s Hospital, we 
will be better able to make conclusions about the roles that the inflammatory biomarkers 
evaluated in this study have in diagnosing and assessing IBD, and their potential to 
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